Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059Jen-Hao Wu, Alwin D. R. Huitema, Kei Fukuhara et al.|Clinical Pharmacokinetics|2024Cited by 6
Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II TrialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Blood|2022Cited by 3